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ABSTRACT
EFFECT OF OBESITY-INDUCED TUMOR NECROSIS FACTOR ALPHA ON
ADIPOCYTE FUNCTION
MAY 2016
SEOK-YEONG YU, B.S., KANGWON NATIONAL UNIVERSITY, KOREA
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST
Directed by Dr. Young-Cheul Kim
Obesity-induced inflammation has been linked to the onset of insulin
resistance (IR), which is a strong risk factor for the development of T2DM. Recent
studies have indicated that tumor necrosis factor alpha (TNFα) plays a causative role
in obesity-mediated IR via its overexpression in adipose tissue. Moreover, TNFα has
been shown to induce the IR and the alteration of lipid and glucose metabolism in
adipose tissue at various levels including normal adipocyte differentiation and mature
adipocyte function. However, the mechanisms linking TNFα-induced adipocyte
dysfunction in chronic obesity to the IR and T2DM are largely unknown. Herein we
report that TNFα inhibited the mRNA expression of PPARγ, which is a key nuclear
transcriptional factor for driving preadipocyte differentiation and maintaining normal
function of mature adipocyte. TNFα treatment suppressed preadipocyte differentiation
by downregulating mRNAs for FAS, perilipin, GLUT4, adiponectin, PGC-1α and
C/EBPα and also altered adipocyte function by inhibiting mRNAs for perilipin,
GLUT4, CPT-1 and PGC-1α, while increasing the expression of IL-6 and MCP1
mRNAs. In palmitic acid (PA)-induced in vitro hypertrophic adipocytes, we found
that mRNA expression of inflammatory cytokines (TNFα and IL-6) was significantly
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elevated, while the expression of mRNAs for PPARγ, perilipin and adiponectin was
markedly reduced, suggesting that TNFα may induce dysfunctional adipocyte
phenotypes by targeting PPARγ and its target genes. In in vivo study, mice fed high
fat diet (HFD) for 16 weeks had adipose tissue dysfunction as reflected by significant
reduction of protein expression for PPARγ, perilipin, FAS and FABP4, consistent
with the results observed in in vitro hypertrophic adipocytes. Interestingly, this was
reversed by the loss of TNFα in TNFα knockout mice, indicating that TNFα may
induce adipocyte dysfunction via the inhibition of PPARγ and its target genes. In the
liver, HFD significantly increased hepatic triglyceride (TG) contents, while
decreasing de novo lipogenesis (SCD1 and FAS), whereas TNFα deficiency
decreased TG content and de novo lipogenesis compared to HFD-fed wild-type (WT)
mice, suggesting that TNFα-induced adipocyte dysfunction is associated with hepatic
lipid deposition in chronic obesity. Taken together, the current findings provide new
insights into the role of TNFα in obesity-induced inflammation and also suggest the
TNFα as a mediator for obesity-induced IR & T2DM.
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CHAPTER
1. PURPOSE OF STUDY
1.1. Overview of Hypotheses
In chronic obesity, hypertrophic adipocytes present altered glucose & lipid
metabolism with increased secretion and expression of proinflammatory cytokines
such as TNFα, IL-6 and MCP1. This obesity-mediated low-grade inflammation has
been demonstrated to be a causative factor of the onset of insulin resistance (IR)
(Samad & Ruf, 2013), which is known to be the primary defect for the development
of type 2 diabetes mellitus (T2DM). However, the mechanisms by which
inflammation contributes to IR in chronic obesity remain unclear.
Among proinflammatory cytokines, tumor necrosis factor alpha (TNFα) has
been proposed as a major candidate gene that links obesity to the onset of IR and
T2DM (Borst, 2004). Overexpression of TNFα in adipose tissue and elevated
systemic TNFα levels have been observed in obese or diabetic humans and animals
(Hotamisligil, Arner, Caro, Atkinson, & Spiegelman, 1995; Hotamisligil, Shargill, &
Spiegelman, 1993; Moon, Kim, & Song, 2004; Salles et al., 2012; Uysal, Wiesbrock,
Marino, & Hotamisligil, 1997). TNFα neutralization in diabetic fa/fa mouse model
significantly improved peripheral glucose uptake in response to insulin (Hotamisligil
et al., 1993). Likewise, insulin-mediated glucose disposal in TNFα knockout mice fed
high fat diet (HFD) for 12 weeks was substantially higher than HFD-fed wild type
mice (Uysal et al., 1997). In addition, circulating free fatty acids levels and hepatic
triglyceride (TG) contents were decreased in TNFα-deficient mice, whereas adipose
tissue weight was increased in the mice (Salles et al., 2012; Uysal et al., 1997),
indicating that TNFα alters adipose tissue function in obesity. Furthermore, TNFα has
1

been shown to inhibit preadipocyte differentiation and mature adipocyte functions
(PPARγ, adiponectin, GLUT4, IR, IRS-1 and perilipin) (Gao, Zuberi, Quon, Dong, &
Ye, 2003; Hotamisligil et al., 1996; Ruan, Hacohen, Golub, Van Parijs, & Lodish,
2002; Yanagisawa et al., 2012), suggesting that TNFα induces insulin resistance and
adipocyte dysfunction, by, at least in part, inducing lipogenic capacity.

Figure 1 TNFα induces adipocyte dysfunction via the inhibition of
PPARγ
Even though the underlying mechanisms by which TNFα impairs normal
adipocyte functions are not fully understood, TNFα-induced suppression of the
expression of PPARγ has been suggested to play a critical role (Guilherme, Virbasius,
Puri, & Czech, 2008). However, it is still unclear if the adipocyte dysfunctions are
directly mediated by TNFα-induced PPARγ inhibition in vitro. In addition, whether
TNFα-suppressed PPARγ expression during preadipocyte differentiation and in
mature adipocytes is a causative factor of IR in vivo has not been investigated.
Therefore, the goal of this work is to elucidate the role of TNFα in adipocyte
in vitro and in vivo to understand the potential mechanism of TNFα-induced IR and
T2DM. Hence, the central hypothesis of this study is that TNFα induces IR in
chronic obesity by inducing altered lipogenic capacity and adipocyte dysfunction.
2

1.2. Specific Aims & Hypothesis
Specific Aim 1 is to test if TNFα induces adipocyte dysfunction and to establish and
characterize in vitro model of hypertrophic adipocytes.

I hypothesize that TNFα causes adipocyte dysfunction through PPARγ inhibition.
Further, I hypothesize that hypertrophic adipocytes present dysfunctional
phenotype with a decrease in PPARγ but an increase in TNFα expression
Rationale: In the literature, TNFα has consistently inhibited preadipocyte
differentiation as well as normal adipocyte function. However, it has been unclear if
TNFα-induced PPARγ inhibition is involved in adipocyte dysfunction.

Specific Aim 2 is to examine the role that TNFα plays in adipose tissue and to
determine the metabolic consequences of TNFα-induced adipocyte dysfunction in
vivo.

Therefore, I hypothesize that obesity-induced TNFα induces adipose tissue
dysfunction via PPARγ inhibition and its downstream target genes involved in
normal adipose function in vivo.
Rationale: In the literature, TNFα has been directly linked to IR and altered lipid
metabolism in the whole body. However, it has not been elucidated if TNFα induces
adipocyte dysfunction in vivo and if TNFα-induced adipocyte dysfunction is involved
in systemic IR.

3

1.3. Significance
The growing prevalence of obesity and type 2 diabetes mellitus (T2DM) is a
major leading public health problem in the U.S. and around the world and the direct
association between obesity-induced IR and T2DM has been long recognized.
Although the precise mechanisms and molecule(s) responsible for this link are still
unclear, altered production of TNFα caused by excess adipose tissue have been
known to contribute to the onset of insulin resistance (IR) and development of T2DM.
Our findings aid in understanding the role of TNFα in obesity-induced IR & T2DM,
which is important to help identify specific targets and molecular mechanisms for
effective intervention and treatment.

4

2. LITERATURE REVIEW
2.1. Obesity & diabetes
2.1.1. Prevalence & Interrelationship
Obesity is characterized by an excessive adipose tissue mass and is a leading
preventable cause of death in the 21st century. The increase in adipose mass results
from both increased adipocyte size (hypertrophy) or increased adipocyte numbers
(hyperplasia) through adipogenesis (Salans, Cushman, & Weismann, 1973). In 2013,
the adult population with body mass index (BMI) of 25 kg/m2 or greater (overweight)
across 183 countries increased up to 36.9% (men) and 38.0% (women) and the
number of obese or overweight people are becoming more prevalent in both
developed countries (Ng et al., 2014). The prevalence of child and adolescent obesity
has increased substantially in developing and developed countries; over 20% in
developed countries and about 13 % in developing countries (Ng et al., 2014). In
addition, the numbers for overweight and obese individuals are estimated to increase
up to 1.35 billion and 573 million worldwide, respectively, by 2030 (Kelly, Yang,
Chen, Reynolds, & He, 2008).
Diabetes is characterized by hyperglycemia and insulin resistance and is a
worldwide public health problem. There are three types of diabetes such as type 1
diabetes mellitus (insulin-dependent diabetes, T1DM), type 2 diabetes mellitus (noninsulin dependent diabetes, T2DM) and gestational diabetes. Among three types of
diabetes, T2DM accounts for approximately 90% of all cases of diabetes. Similar to
obesity, the prevalence of T2DM has rapidly increased since 1980 and it is estimated
to further increase from 382 million (in 2013) to 592 million by 2035 across 130
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countries (Guariguata et al., 2014). The global prevalence of T2DM is also becoming
higher in both developing and developed countries (Guariguata et al., 2014).
According to the map showing trends in diabetes & obesity from Centers for
Disease Control and Prevention (CDC, http://www.cdc.go/diabetes/statistics), the
growth rate of obese population (BMI≥ 30 kg/m2) in the U.S. has been almost
doubled between 1994 and 2013; 26% or greater obese population in 38 states, 22 to
25.9% obese population in 11 states, and 18 to 21.9% obese population in 2 states.
Similarly, the prevalence of T2DM grew rapidly in nearly all the states; more than 9%
diabetic population in 25 states, 7.5 to 8.9% diabetic population in 19 states and 6.0 to
7.4% diabetic population in 7 states, and it presents a similar trend to the increase in
obesity prevalence across all the states during the time period. Although the
relationship between obesity & diabetes is interdependent, the clear mechanisms
linking these two conditions remain unclear. It is therefore important to understand
the pathogenesis of obesity-mediated T2DM for effective prevention & treatment
options.

2.1.2. Obesity-induced insulin resistance and T2DM
Although the exact mechanism of obesity-mediated T2DM has been unclear,
obesity-induced IR has been believed to be a critical factor that contributes to the
development of T2DM. IR is a condition in which insulin-mediated glucose disposal
in the body is impaired and is highly associated with the severity of obesity. GarciaEstevez and the co-workers (Garcı́a-Estévez, Araújo-Vilar, Saavedra-González,
Fiestras-Janeiro, & Cabezas-Cerrato, 2004), for example, reported that insulin
sensitivity index as measured by oral glucose tolerance test is dramatically decreased
as BMI increased and that the amount of insulin secreted was significantly increased
6

from BMI 29.3 to 45 kg/m2, whereas this was consistent between BMI 18 to 29.3
kg/m2. In addition, obesity-induced IR has been positively correlated with waist
circumference (WC), plasma free fatty acids (FFAs), triglyceride (TG) and
proinflammatory cytokines levels (Aslam, Aggarwal, Sharma, Galav, & Madhu, 2016;
Boden & Shulman, 2002; Greco et al., 2002; Xu et al., 2015), all of which are the risk
factors for the development of T2DM. Although most patients with T2DM are obese,
not all obese individuals develop T2DM later in their lives, suggesting that
environmental factors such as diets and sedentary behavior interact with a genetic
predisposition during the development of T2DM. Therefore, identifying factors that
underlie insulin resistance in obesity will be essential to advance the effective
interventions.
In an attempt to elucidate the complexity of the progression of obesity to
T2DM, many risk factors have been investigated and identified such as circulating
FFAs, adipokines and ectopic fat deposition to the liver and muscle (Kralisch et al.,
2007; Petersen et al., 2005; Roden et al., 1996). These factors are inter-independent
and positively correlated with the whole-body insulin resistance in the patients with
T2DM.

Ø Free fatty acids (FFAs): Elevated plasma FFAs levels have been observed in
obese and diabetic states. (Boden, 2011; Savage, Petersen, & Shulman, 2007).
The concentration of FFAs in the circulation is determined by the dynamics
between the release of FFAs from adipocytes and FFAs clearance from the
circulation. In obesity and T2DM, however, chronically elevated FFAs inhibit
insulin-mediated antilipolytic action and in turn perturb the turnover rate of FFAs
in adipocytes (Bjorntorp, Bergman, & Varnauskas, 1969; Jensen, Haymond,
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Rizza, Cryer, & Miles, 1989). This also causes insulin resistance through the
inhibition of glucose translocation in skeletal muscle and stimulation of
glycogenolysis, glycogen breakdown, suggesting failure of FFAs clearance
mediate insulin resistance in obesity (Boden, Chen, Capulong, & Mozzoli, 2001;
Dresner et al., 1999).

Ø Adipokines: Adipokines refers to cytokines secreted from adipose tissue.
Adiponectin is known as adipoQ and a key regulatory protein for systemic insulin
sensitivity. The biological roles of adiponectin are to increase FFA oxidation in
the liver and muscle tissues through adiponectin receptor 1 & 2 (AdipoR1 & 2)
and also to stimulate the clearance rate of FFAs, TG and glucose from the blood
(Cnop et al., 2003; Kadowaki & Yamauchi, 2005; Liu et al., 2012; Polyzos,
Kountouras, Zavos, & Tsiaousi, 2010). However, the plasma level of adiponectin
is lower in obese and diabetic individuals (Hara et al., 2003; Yu et al., 2002).
Plasma adiponectin level is inversely correlated with plasma TG, free fatty acids
levels and insulin resistance (Cnop et al., 2003; Engeli et al., 2003; MedinaUrrutia et al., 2015). In in vivo study with rhesus monkeys, Hotta and the coworkers (Hotta et al., 2001) demonstrated that plasma adiponectin levels were
decreased in primates before the onset of diabetes and persisted even after the
onset. By comparing the rate of glucose clearance from blood between
hyperadiponectinemia and hypoadiponectinemia in obese monkeys, they found
that hypoadiponectinemia had significantly lower glucose disposal rate, indicating
adiponectin is closely associated with systemic insulin sensitivity.
Inflammatory cytokines such as TNFα and Il-6 are also included in adipokines
due to that they are overexpressed from adipose tissue in obese and diabetic

8

humans and animals (Barbarroja et al., 2010; Chang et al., 2015; Kern,
Ranganathan, Li, Wood, & Ranganathan, 2001; Kuo, Chang, Tsai, & Lee, 2012).
It could be attributed to the fact that macrophages are infiltrated into adipose
tissue and activated while increasing the expression of proinflammatory cytokines
(Heilbronn & Campbell, 2008). However it has been reported that enlarged and
hypertrophic adipocytes overexpress TNFα, MCP1, IL-6, serum amyloid A
(SAA), plasminogen activator inhibitor-1 (PAI-1), and hyaluronan (HA) in vitro
(Han et al., 2007; Jernas et al., 2006; Kim et al., 2015). In addition, the size of
adipocyte was highly associated with plasma IL-6, TNFα and insulin resistance in
obese individuals (Maffeis et al., 2007).
Taken together, these observations reinforce the function of adipose tissue in
metabolic homeostasis through sequestration of fat and normal secretion of
adipokines as supported by the demonstration that the loss of adipose tissue
function increases the risk factors for T2DM (Moitra et al., 1998; Sovik,
Vestergaard, Trygstad, & Pedersen, 1996; Vigano et al., 2011).
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2.2. The physiological role of adipose tissue
Adipose tissue is a specialized connective tissue that serves as a major energy
reservoir in the body. Adipose tissue is classified into brown adipose tissue (BAT)
and white adipose tissue (WAT) by the physiological characteristics in the body, but
WAT is the major tissue that constructs the body’s adipose tissue. Over the past
decade, the perspective on adipose tissue (WAT) is changed from a fat store to a
complex endocrine organ because it secrets adipokines, such as adiponectin that plays
an important role in the whole body energy metabolism and homeostasis.
In adipose tissue, there are many different types of cells such as adipocyte,
preadipocytes and non-adipose cells such as lymphocytes, neutrophils, endothelial
cells and macrophages but adipose tissue is mainly made up of adipocytes. In our
body, adipose tissue is distributed in many different sites throughout the body such as
subcutaneous layers, around heart, kidneys and internal organs to provide insulation
and mechanical support. However, the most important role of adipose tissue in the
body is (1) to esterify and store TGs during a feeding state and (2) to de-esterify and
release FFAs into the circulation during a fasting state. Even though the release of
FFAs increases during a fasting state, the fasting fatty acid is taken up into the liver,
muscle and heart to esterify with coenzyme A and to oxidize it in mitochondria. On
the other hand, during feeding, the concentration of FFAs and glucose in the
circulation is regulated by insulin, whose actions are to increase the uptake of glucose
and FFAs in adipose tissue and to inhibit lipolysis in adipocytes.
Adipose tissue function is There are two ways to store the energy in the body,
such as hyperplasia which is the process to increase the number of adipocytes through
preadipocyte differentiation and adipocyte hypertrophy which is the process to
enlarge adipocyte itself. The process of preadipocyte differentiation has been
10

investigated using reliable in vitro cell model which is 3T3-L1 preadipocyte from 3T3
mouse embryo fibroblasts.

Figure 2. Differentiation process of 3T3-L1 preadipocytes into adipocytes
(Ntambi & Young-Cheul, 2000)
3T3-L1 preadipocytes are differentiated into adipocyte with morphological changes
by adipogenic cocktail including insulin, a glucocorticoid and 3-isobutyl-1methylxanthine. Once confluent 3T3-L1 preadipocytes are exposed to the adipogenic
cocktail, the cells undergo a complex cell signaling event including postconfluent
mitosis and growth arrest and differentiate into adipocytes through a series of
transcriptional steps as described in Fig.1. Among adipogenic transcription factors,
the importance of PPARγ has been notably known for the regulation of cell
differentiation and metabolism such as lipogenic genes such as FAS, GLUT4 and
adiponectin. In addition, PPARγ plays an important role in the maintenance of mature
fat cell functions. Tamori and the co-workers (Tamori, Masugi, Nishino, & Kasuga,
11

2002) created PPARγ mutant 3T3-L1 adipocytes and found that the mutation of
PPARγ in adipocytes increased the rate of lipolysis and caused a reduction in the
uptake of free fatty acids. Also, it decreased the expression of GLUT4, insulin
receptor, and insulin receptor substrate (IRS).

2.3. Insulin-resistant obesity: Adipose tissue & adipocyte
Over the past decade, it has been suggested that inflammation plays an
important role in the onset of insulin resistant (Samad & Ruf, 2013). Recently, it has
been increasingly evident that inflammation-induced adipocyte dysfunction links
obesity to insulin resistance (Guilherme et al., 2008). This is also strongly supported
by a large body of evidence that PPARγ agonist reverses adipocyte dysfunction in IR
(Mayerson et al., 2002; Tiikkainen et al., 2004), further suggesting the role of PPARγ
in obesity-induced IR.

2.3.1. Inflammation and adipose tissue
Adipose tissue is an insulin-sensitive tissue and the major site where the body
stores the energy in a highest density. Adipose tissue function properly controls the
whole body lipid and glucose metabolism in response to insulin. However, in obesity,
prolonged excessive energy induces abnormally enlarged and hypertrophied
adipocytes. The plasma adiponectin, which is associated with systemic insulin
sensitivity, is downregulated and adipocyte lipolysis is stimulated (Kennedy, Martinez,
Chuang, LaPoint, & McIntosh, 2009; Meyer, Ciaraldi, Henry, Wittgrove, & Phillips,
2013). In addition, macrophages are infiltrated into adipose tissue and become
activated. Vicious cycle is created between hypertrophic adipocytes and macrophages
by secreting proinflammatory cytokines such as tumor-necrosis factor alpha (TNFα)

12

and interleukin 6 (IL-6) (Suganami & Ogawa, 2010). Therefore, low-grade

Figure 3. Obesity-induced hypertrophic adipocye and low-grade
inflammation (Samad & Ruf, 2013)
inflammation is created in obesity and it causes insulin resistance locally and
systemically. Among many proinflammatory cytokines, TNFα has been recently
suspected of the causative factor that induces insulin resistance in obesity.

2.3.2. The role of TNFα in obesity
TNFα is one of the key regulators of inflammatory response and originally
thought to be associated with cachexia. However, it has been now recognized as a
critical factor involved in insulin resistance in obesity.
In clinical trials, systemic TNFα levels are positively correlated with BMI,
WC and body fat mass (%) (Moon et al., 2004). In addition, it showed a positive
correlation with plasma insulin, glucose and the size of adipocytes (Bahceci et al.,
2007; Nilsson, Jovinge, Niemann, Reneland, & Lithell, 1998). Adipose tissue TNFα
13

expression is also increased in obese groups (Hotamisligil et al., 1995). In addition, it
has shown a positive correlation with body fat (%), plasma insulin and glucose levels
(Hotamisligil et al., 1995; Kern et al., 1995).
In in vivo studies, fa/fa mouse model has been shown that genetically develops
T2DM and IR with adipose tissue TNFα expression increased (Hotamisligil et al.,
1993). However, TNFα neutralization significantly improved glucose disposal in
peripheral tissues and high concentration of the TNFα-neutralizing agent further
increased glucose uptake into peripheral tissues in the mice (Hotamisligil et al., 1993).
In addition, high-fat diet (HFD)-fed TNFα-deficient mice had improved insulin
sensitivity, decreased the mRNA expression of proinflammatory cytokines (IL-6,
MCP1 and SAA) and circulating free fatty acids (FFAs) levels (Salles et al., 2012;
Uysal et al., 1997).
In in vitro models, TNFα inhibited 3T3-L1 preadipocyte differentiation (Chae
& Kwak, 2003). In mature adipocytes, TNFα inhibited insulin signaling pathway by
decreasing the protein expression of insulin receptor substrate 1 (IRS-1) and
increasing serine phosphorylation of insulin receptor (Hotamisligil et al., 1996). In
addition, TNFα significantly decreased the expression levels of glucose transporter 1
& 4 (GLUT1 & GLUT4) and adiponectin (Stephens, Lee, & Pilch, 1997). However,
the evidence of underlying mechanisms by which TNFα alters adipocyte functions is
unclear.

2.3.3. Therapeutic approaches against the action of TNFα
Even though the mode of action of TNFα in IR is unclear, there have been
many observations that synthetic and natural bioactive compounds attenuate IR in
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obesity and T2DM. The evidence could give us an insight into the ways to prevent
and treat IR and T2DM.

Ø Drugs: Sodium salicylate, an anti-inflammatory drug, has been shown to reduce
urinary glucose excretion in T2DM patients (Ebstein, 1876; Williamson, 1901).
Aspirin (~ 6 g/d), one of salicylates, also causes a reduction in fasting plasma
glucose, TG and fatty acid levels in diabetic patients (Hundal et al., 2002). But at
low-dose between 81 to 100 mg per day aspirin did not alter the plasma
parameters (Ogawa et al., 2008). In 3T3-L1 adipocytes, aspirin antagonized
TNFα-induced impairment of insulin signaling pathway by blocking mediated
NF-κB signaling pathway, which is activated by TNFα in vitro (Gao et al., 2003).
In addition, transfected adipocytes with a non-degradable mutant of IκBα which
blocks NF-κB signaling showed upregulation of GLUT4 (Ruan et al., 2002),
suggesting that TNFα-mediated NF-κB signaling impairs adipocyte functions.
TZDs are anti-diabetic drugs with insulin-sensitizing effects by targeting
PPARγ in diabetic patients. The treatment with TZDs has been shown to reduce
plasma TG, FFAs and insulin in obese and diabetic individuals (Mayerson et al.,
2002; Yu et al., 2002). It has also shown the antagonizing effects on the action of
TNFα. TZDs such as pioglitazone (Pio) increased the downregulation of IRS-1
and insulin receptor protein expression by TNFα in adipocytes in vitro (Iwata et
al., 2001). However, Pio did not alter TNFα-mediated NF-κB signaling pathway,
suggesting that PPARγ is an intermediate gene between NF-κB signaling
cascades and insulin signaling pathway. However, aspirin worked at a high
concentration that might lead to the adverse effects such as gastrointestinal tract
bleeding and also it showed that aspirin resistance occurs commonly in diabetic
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patients. In addition, TZDs treatment accompanies significant weight gain (FatehMoghadam et al., 2005; Fonseca, 2003).

Ø Bioactives: Phytoestrogens (isoflavones) are plant-derived compounds with
partial estrogenic effects due presumably to structurally similarity to endogenous
estrogen, estradiol. The bioactive compounds are abundant in legumes, red clover
and soy-containing foods. Besides the partial estrogenic effects, isoflavones are
well known for PPARs activator. In obesity, soy consumption is inversely
correlated with the prevalence of obesity across 167 countries (Dante & Maciej,
2012), suggesting that soy consumption lowers adiposity in the body. In vivo
study with Zucker rat which is used as an genetically-induced obese metabolic
syndrome model, Mezei and co-workers (Mezei et al., 2003) demonstrated that
high-isoflavone soy protein (HIS) were significantly reduced hepatic cholesterol
and TG levels compared to low-isoflavone soy protein (LIS) and control groups
in male and female rats. In oral glucose tolerance test in obese Zucker rats, HIS
also significantly improved glucose intolerance. In another genetic model (obese
SHR/N-cp rats), isoflavones (genistein, daidzein and glycetin) administration for
20 weeks significantly lowered plasma total cholesterol and LDL levels but
increased HDL cholesterol levels (Ali, Velasquez, Hansen, Mohamed, &
Bhathena, 2004). In addition, genistein or daidzein alone significantly reduced
HFD-induced body weight and adiposity in mice (Ae Park et al., 2006),
suggesting that isoflavones could be the beneficial factor that reduces the
incidence of obesity.
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Figure 4. The role of isoflavones in PPAR signaling. (Patel & Barnes, 2010)

In diabetes, legume and soy food intake reduced the onset of T2DM in the
women living in the Shanghai (Villegas et al., 2008). Also, the association between a
higher intake of soy product and a lower risk of T2DM among overweight Japanese
women has been observed (Nanri et al., 2010). In db/db mice, genistein and daidzein
significantly improved plasma HbA1c levels and hepatic glucokinase activity (M. S.
Choi, Jung, Yeo, Kim, & Lee, 2008). Genistein lowered hyperglycemia and oxidative
stress and also reduced plasma TNFα, IL 1β and IL-6 in streptozotocin (STZ)-induced
diabetic mice (Valsecchi et al., 2011). Besides to soy isoflavones, red clover extract
rich in formononetin and biochanin A reduced plasma TG, total and LDL-cholesterol
levels in STZ-induced diabetic mice (Qiu, Chen, et al., 2012; Qiu, Ye, et al., 2012).
Also isoflavones such as formononetin or biochanin A alone also attenuated plasma
hyperlipidemia suggesting isoflavones as the bioactives exerting anti-diabetic effects.
However, the underlying mechanism of isoflavones-induced anti-obesity or antidiabetic effects has remained unclear.
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3. IN VITRO STUDY: THE EFFECTS OF TNFα IN ADIPOCYTE
FUNCTION
3.1. Materials
Oil Red O (ORO), palmitate, 3-isobutyl-1-methylxanthine (IBMX), dexsamethasone
(DEX) and insulin (INS) were purchased from Sigma Chemical Co. (St Louis, MO,
USA). Rhe fast SYBR real-time PCR master mix, TNFα Dulbecco’s modified Eagle’s
medium (DMEM), fetal bovine serum (FBS), newborn calf serum (NCS), penicillinstreptomycin (P/S), and trypsin-EDTA were obtained from Life Technologies (Grand
Island, NY, USA). The specific primers for quantitative real-time PCR were designed
using

PrimerQuest

(Integrated

DNA

Technologies;

https://www.idtdna.com/Primerquest/Home/Index and obtained from integrated DNA
Technologies (Coralville, Iowa, USA) and the primer sequences used are provided in
Table 1.

Table 1 PCR primer sequences for real-time PCR analysis
PPARγ
Perilipin
FAS
GLUT4
AdipoQ3)
CPT-1
PGC-1α
SCD-1
1)

F1)
R2)
F
R
F
R
F
R
F
R
F
R
F
R
F
R

TCGGTTTCAGAAGTGCCTTG
GATCTCCGCCAACAGCTTC
CCTCTGTGTGCAATGCCTAT
CTCTGCAGGCCAACTCATT
CTGTACGGGATCATACTGGTTC
CAGAGCGCTGGTCATGTA
GCTTGGCTCCCTTCAGTTT
CCAGCCACGTTGCATTGTA
GAGAGAAGGGAGAGAAAGGAG
CAGCTCCTGTCATTCCAACA
CTGGATGTTTGCAGAGCAC
GCTGTACAACATGGGCTTTC
CGATCACCATATTCCAGGTCAAG
AAGGGAGAATTGCGGTGTG
CACAGATGATGACAGGAGATGG
AAAGGAGGCGTCGAACTTG

Forward
Reverse
3)
Adiponectin
2)
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β-actin
C/EBPα
IL-6
MCP1
TNFα
DGAT1
ATGL
-

F
R
F
R
F
R
F
R
F
R
F
R
F
R

CAGCCTTCCTTCTTGGGTATG
CGGATGTCAACDTCACACTT
GAACGCAACAACATCGC
CACCTTCTGTTGCGTCT
TTGCCTTCTTGGGACTGATG
AGGTCTGTTGGGAGTGGTAT
CRCACCTGCTGCTACTCATTC
ACTACAGCTTCTTTGGGACAC
GCCTCCCTCTCATCAGTTCTA
CACTTGGTGGTTTGCTACGA
CCAGCAAGCTGTGAGCTAT
GGACCGAGGAAAGTTGAGTT
TCCAGTTCAACCTTCGCAAT
CCATCTCTGTAGCCCTGTTTG

-

3.2. Experimental design
3.2.1. TNFα treatment during preadipocyte differentiation

Figure 5. Experimental design of TNFα treatment
during 3T3-L1 preadipocyte differentiation

3T3-L1 cells (ATCC® CL-173TM) were used below passage 12. 3T3-L1
preadipocytes were propagated and cultured in DMEM medium supplemented with
10% NCS and 1% P/S until confluent, further maintained for additional 2 days and
differentiated in DMEM containing 10% FBS and 1% P/S for 6 days. The medium
was changed every other day.

3.2.2. TNFα treatment in mature adipocyte

Figure 6. Experimental design of TNFα treatment
to mature adipocyte
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Once 3T3-L1 preadipocytes were fully differentiated into adipocytes, the cells
were serum-starved in serum-free, high-glucose DMEM with 1% P/S for 24 h. After
serum starvation, the cells were exposed to TNFα for 6 h and then harvested.

3.2.3. Characterization of hypertrophic adipocyte

Figure 7 Experimental design of the induction of adipocyte
hypertrophy

Fully differentiated adipocytes were exposed to palmitic acid (250 µM) to
induce hypertrophic adipocytes as reported. The medium was daily changed and the
cells were harvested after 6 days.

3.3. Methods
Ø Oil Red O (ORO) staining. To determine the degree of differentiation as
measured by intracellular lipid content, ORO was performed. Briefly, 3T3-L1
adipocytes were washed with 4% paraformaldehyde once and fixed with 4%
paraformaldehyde for 20 min at room temperature. Cells were then washed with
60% isopropanol once and stained with diluted Oil Red O solution for 30 min.
After photographing the stained cells, the dye retained in 3T3-L1 cells was eluted
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with 100% isopropanol and absorbance was measured by a microplate reader
(SpectraMax M2, Molecular Devices, Sunnyvale, CA) at 490 nm.

Ø Quantitative real-time PCR. Total RNA was isolated with TRIzol® according to
manufacturer’s protocol (Life technologies, Grand Island, NY). 1 µg of total
RNA was used to synthesize cDNA using RevertAid First Strand cDNA
Synthesis kit (Thermo Scientific, Waltham, MA). The reaction was performed
with Fast SYBR® Green Master Mix containing 1 µM of primer pair and 100 ng
of cDNA under 40 cycles with each of 95 °C for 1 sec and 58 °C for 20 sec.
Relative levels of the target mRNA expression were determined by ViiATM 7
real-time PCR system (Life technologies, Grand Island, NY), normalized to
GAPDH or β-actin and calculated with the 2-(ΔΔnd) method.

3.4. Statistical analysis.
All statistical analyses were performed in Excel and statistical significances
were evaluated with independent t-test.
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3.5. Results

3.5.1. TNFα inhibited preadipocyte differentiation.
In order to investigate if TNFα induces adipocyte dysfunction through the
inhibition of preadipocyte differerntiation, first the inhibitory effects of TNFα on
preadipocyte differentiation was evaluated. Widely used concentration of TNFα, 10
ng/mL (Chae & Kwak, 2003), was selected and preadipocytes were differentiated into
adipocytes in presence or absence of TNFα for 6 days. The cells were then stained
with ORO. As shown in Fig. 8, the picture of ORO stained-cells indicates that about
50% of preadipocytes were differentiated into adipocytes at day 6 of the
differentiation. However, the differentiation of TNFα-treated preadipocytes was
noticeably inhibited compared to the picture of control cells. The TNFα-induced
relative inhibition was about 60% at day 5 (p <0.001).
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Figure 8. The effects of TNFα during 3T3-L1 preadipocyte differentiation. On
day 5 of differentiation, intracelluar lipid droplets were stained with ORO
solution for 30 min air-dried overnight. After then the picture of the plate with
ORO-stained cells was scanned and eluted with 100% isopropanol. The
expriment was repeated three times. Each bar represents a mean ± S.E.
Significant difference was determined by independet t-test (*p<0.05 vs. control,
**p<0.01vs. control, ***p<0.001 vs. control)

3.5.2. TNFα inhibited the expression of major transcriptional factors for
adipocyte differentiation.
In an mRNA level, the inhibitory effects of TNFα on preadipocyte
differentiation were confirmed. As shown in Fig. 9, TNFα significantly suppressed
the mRNA expression levels of PPARγ and C/EBPα (p <0.001) which are the key
nuclear transcriptional factors for preadipocyte differentiation while inducing the
mRNA expression levels of IL-6 and MCP1 (p <0.001) which are well known for
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TNFα target gene, suggesting that TNFα inhibits preadipocyte differentiation through
the inhibition of endogenous elements for the differentiation.

Figure 9. TNFα-induced changes in gene expression of PPARγ, C/EBPα, IL-6
and MCP1 during preadipocyte differentiation. At day 5, the cells were
harvested with TRizol and used for RT-PCR as described Methods. The
expriment was repeated three times and the data resented are relative values
expressed in relation to endogenous β-actin (mean±S.E.). Significant difference
was determined by independent t-test (*p<0.05 vs. control, **p<0.01vs. control,
***p<0.001 vs. control)

3.5.3. PPARγ downstream target genes were inhibited in the presence of TNFα
during preadipocyte differentiation.
To assess if the inhibition of preadipocyte differentiation by TNFα is a
potential mechanism for TNFα-induced adipocyte dysfunction, the genes related to
lipid and glucose metabolism in adipocyte were analyzed. As shown in Fig. 10, TNFα
induced a progressive decrease in the mRNA expression levels of FAS and perilipin
(p <0.001), which are involved in lipid synthesis and coating. In addition, TNFα
suppressed the mRNA expression levels of GLUT4 and adiponectin (p <0.001).
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Figure 10. TNFα treatment results in the downregulation of PPARγ downstream
target genes during preadipocyte differentiation. At day 5, the cells were
harvested with TRizol and used for RT-PCR as described Methods. The
expriment was repeated three times and the data resented are relative values
expressed in relation to endogenous β-actin (mean±S.E.). Significant difference
was determined by independent t-test (*p<0.05 vs. control, **p<0.01vs. control,
***p<0.001 vs. control)

3.5.4. PGC-1α only was inhibited by TNFα during preadipocyte differentiation.
To ascertain the effects of TNFα-inhibited preadipocyte differentiation on
lipid metabolism, lipid oxidation-related genes such as carnitine palmitoyltransferase
1(CPT1) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha
(PGC-1α) were analyzed. TNFα significantly inhibited PGC-1α mRNA (p<0.001) but
did not affect the mRNA expression of CPT-1 during preadipocyte differentiation.
Since CPT-1 expression is not altered during preadipocyte differentiation (Brown et
al., 1997), our data clearly indicate that TNFα impairs adipocyte functions through the
inhibition of preadipocyte differentiation and.
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Figure 11. TNFα does not affect the mRNA expression of CPT-1 but PGC-1α
during preadipocyte differentiation. At day 5, the cells were harvested with
TRizol and used for RT-PCR as described Methods. The expriment was repeated
three times and the data resented are relative values expressed in relation to
endogenous β-actin (mean±S.E.). Significant difference was determined by
independent t-test (*p<0.05 vs. control, **p<0.01vs. control, ***p<0.001 vs.
control)

3.5.5. TNFα also inhibited PPARγ gene expression in mature adipocyte.
Even though adipocyte functions are maintained through preadipocyte
differentiation, adipose tissue functions are represented by adipocyte functions. Thus,
the effects of TNFα on adipocyte functions were evaluated. To this end, if PPARγ
mRNA is altered during TNFα stimulation as the endogenous expression is an
essential for adipocyte to function was investigated. The mRNA expression of PPARγ
was decreased after 3 h treatment of TNFα and the expression was further decreased
up to 50 % after 6 h (p<0.001). However, no further decrease was induced after 9 h
treatment of TNFα. Thus, 6 h treatment was selected and used for further study.
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Figure 12. Effect of TNFα on PPARγ expression in mature adipocytes. Fully
differentiated 3T3-L1 adipocytes were serum-starved for 24 h and then treated
with TNFα (10 ng/mL) for the indicated time periods in the presence of insulin
(167 nM). Total RNAs were isolated and subject to RT-PCR as described in
Methods. The expriment was repeated three times in duplicate and the data
resented are relative values expressed in relation to endogenous β-actin
(mean±S.E.). Significant difference was determined by independent t-test
(*p<0.05 vs. control, **p<0.01vs. control, ***p<0.001 vs. control)

3.5.6. TNFα increased its target proinflammatory genes expressed in mature
adipocytes.
To ascertain whether TNFα induces the mRNA expression of IL-6 and MCP1
in adipocytes as observed during preadipocyte differentiation, TNFα-treated
adipocytes were analyzed. As shown in Fig. 13, the mRNA expression of IL-6 and
MCP1 were significantly increased after 6 h in adipocytes. IL-6 mRNA expression
was upregulated nearly 13-fold (p<0.001). In addition, the mRNA expression of
MCP1 was increased about 5-fold (p<0.001) compared to non-TNFα-treated
adipocytes, suggesting TNFα induces the expression of inflammatory cytokines while
impairing adipocyte functions.
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Figure 13. TNFα increases the expression of IL-6 and MCP1 in mature adipocyte.
Fully differentiated 3T3-L1 adipocytes were serum-starved for 24 h and then
treated with TNFα (10 ng/mL) for 6 h in the presence of insulin (167 nM). Total
RNAs were isolated and subject to RT-PCR as described in Methods. The
expriment was repeated three times in duplicate and the data resented are
relative values expressed in relation to endogenous β-actin (mean±S.E.).
Significant difference was determined by independent t-test (*p<0.05 vs. control,
**p<0.01vs. control, ***p<0.001 vs. control)

3.5.7. Perilipin and GLUT4 were decreased by TNFα in mature adipcoytes.
To assess the inhibitory effects of TNFα on adipocyte functions, the genes
related to adipocyte functions such as lipid and glucose metabolism were analyzed
(Fig. 14). The mRNA expression of perilipin and GLUT4 were significantly inhibited
in the presence of TNFα (p<0.001). However, TNFα did not affect the expression of
FAS and adiponectin, consistent with the observation that FAS and adiponectin
expression are not affected by PPARγ expression (J. H. Choi et al., 2010; Tan et al.,
2005). Thus these data indicate that TNFα impairs adipocyte functions via PPAR
inhibition.
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Figure 14. TNFα does not affect the expression of FAS and adiponectin but alters
perilipin and GLUT4 expression in mature adipocytes. Fully differentiated
3T3-L1 adipocytes were serum-starved for 24 h and then treated with TNFα (10
ng/mL) for 6 h in the presence of insulin (167 nM). Total RNAs were isolated
and subject to RT-PCR as described in Methods. The expriment was repeated
three times in duplicate and the data resented are relative values expressed in
relation to endogenous β-actin (mean±S.E.). Significant difference was
determined by independent t-test (*p<0.05 vs. control, **p<0.01vs. control,
***p<0.001 vs. control)

3.5.8. Lipid oxidation-related genes were inhibited in the presence of TNFα in
mature adipocytes.
To ascertain the inhibitory effects of TNFα on adipocyte function, lipid
oxidation-related genes were also analyzed after 6 h treatment of TNFα. Unlike the
data from preadipocyte differentiation, TNFα treatment significantly downregulated
the mRNA expression of CPT1 and PGC-1α both in mature adipocytes (p<0.001),
suggesting the differential modes of action of TNFα that induces adipocyte
dysfunction through the inhibition of adipocyte PPARγ and preadipocyte
differentiation.

29

.
Figure 15. Effects of TNFα on the mRNA expression of CPT1 and PGC-1α in
mature adipocytes. Fully differentiated 3T3-L1 adipocytes were serum-starved
for 24 h and then treated with TNFα (10 ng/mL) for 6 h in the presence of
insulin (167 nM). Total RNAs were isolated and subject to RT-PCR as described
in Methods. The expriment was repeated three times in duplicate and the data
resented are relative values expressed in relation to endogenous β-actin
(mean±S.E.). Significant difference was determined by independent t-test
(*p<0.05 vs. control, **p<0.01vs. control, ***p<0.001 vs. control)

3.5.9. Palmitic acid induced hypertrophic adipocytes concomitant with increased
expression of proinflammatory cytokines.
Since obesity is characterized by hypertrophic adipocytes and chronic
inflammation state, in vitro TNFα treatment will represent acute inflammatory
response of normal adipocytes. Thus, the characteristics of in vitro lipid-overloaded
adipocytes which represent hypertrophic adipocytes in obesity were investigated to
confirm the TNFα-induced characteristic changes in gene expression previously (Fig.
8-15). To this end, adipocytes were exposed to palmitic acid (PA) at 250 µM to
induce hypertrophic adipocytes that overexpress proinflammatory cyoktines such as
TNFα as described in previous studies (Han et al., 2007; Kim et al., 2015). As shown
in Fig. 16, PA-treated adipocytes showed a big lipid droplet and a bigger size of
30

adipocytes compared to nonPA-treated cells. In addition, hypertrophic adipocytes
significantly increased the mRNA expression of TNFα (p<0.05) and IL-6 (p<0.001),
suggesting that obesity-induced hypertrophic adipocytes are established in vitro.

Figure 16. PA-induced in vitro hypertrophic adipocytes mimics adipose tissue
low-grade inflammation in obesity. At day 8 after differentiation, the cells
were exposed to PA at 250 µM for additional 6 days to induce hypertrophic
adipocytes. Total RNAs were isolated and subject to RT-PCR as described in
Methods. The expriment was repeated three times in duplicate and the data
resented are relative values expressed in relation to endogenous β-actin
(mean±S.E.). Significant difference was determined by independent t-test
(*p<0.05 vs. control, **p<0.01vs. control, ***p<0.001 vs. control).
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3.5.10. Hypertrophic adipocytes induced dysfunctional adipocyte phenotypes.
To assess if chronic inflammatory state during the induction of adipocyte
hypertrophy indeed induces adipocyte dysfunction as observed in in vitro TNFα
treatment studies during preadipocyte differentiation and in mature adipocyte, the
major genes for adipocyte function were analyzed, such as PPARγ, perilipin and
adiponectin. As shown in Fig. 17, hypertrophic adipocytes showed a significant
reduction in the levels of PPARγ (p<0.05), perilipin (p<0.01) and adiponectin
(p<0.05), indicating that in vitro hypertrophic adipocytes are characterized by
overexpression of proinflammatiory cytokines but by dysregulation of adipocyte
functions.

Figure 17. PA-induced changes in gene expression of PPARγ, perilipin and
adiponectin. At day 8 after differentiation, the cells were exposed to PA at 250
µM for additional 6 days to induce hypertrophic adipocytes. Total RNAs were
isolated and subject to RT-PCR as described in Methods. The expriment was
repeated three times in duplicate and the data resented are relative values
expressed in relation to endogenous β-actin (mean±S.E.). Significant difference
was determined by independent t-test (*p<0.05 vs. control, **p<0.01vs. control,
***p<0.001 vs. control).
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4. IN VIVO STUDY: THE ROLE OF TNFα IN HIGE-FAT DIET
(HFD)-INDUCED OBESITY
4.1. Materials
Triglyceride content measurement kit was purchased from Sigma Chemical
Co.(St Louis, MO, USA) and the fast SYBR real-time PCR master mix was obtained
from ife Technologies (Grand Island, NY, USA). Antibodies against fatty acid
binding protein 4 (FABP4), perilipin and fatty acid synthase (FAS) were purchased
from Cell signaling technology (Beverly, MA, USA). Antibodies against peroxisome
proliferator-activated receptor gamma (PPARγ), and β-actin were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).
4.2. Experimental design
All experimental procedures were approved by the Institutional Animal Care
and Use Committee of the Jean Mayer USDA human Nutrition Research Center on
Aging at Tufts University. C57BL/6 mice were used in this study. At age of 6 weeks,
the mice were divided into three groups (6 mice per group): wild-type mice
administered with a low-fat diet (10% of total kcal as fat), WT-LF; wild-type mice
administered with a high-fat diet (60% of total kcal as fat), WT-HF; TNFα knockout
mice administered with a high-fat diet, TNFα KO-HF. Obesity was induced for 16
weeks (from age of 6 to 18 weeks). At the time of sacrifice, adipose tissues were
frozen in liquid nitrogen and stored at - 80˚C.

4.3. Methods
Ø Triglyceride (TG) content measurement. Liver TG contents were measured by TG
content measurement kit from Sigma Chemical Co.(St Louis, MO, USA). Sample TG
33

contents were compared with a TG standard curve which is measured by a microplate
reader (SpectraMax M2, Molecular Devices, Sunnyvale, CA) at 570 nm.

Ø Quantitative real-time PCR. Total RNA was isolated with TRIzol® according to
manufacturer’s protocol (Life technologies, Grand Island, NY). 1 µg of total RNA
was used to synthesize cDNA using RevertAid First Strand cDNA Synthesis kit
(Thermo Scientific, Waltham, MA). The reaction was performed with Fast SYBR®
Green Master Mix containing 1 µM of primer pair and 100 ng of cDNA under 40
cycles with each of 95 °C for 1 sec and 58 °C for 20 sec. Relative levels of the target
mRNA expression were determined by ViiATM 7 real-time PCR system (Life
technologies, Grand Island, NY), normalized to GAPDH or β-actin and calculated
with the 2-(ΔΔnd) method.

Ø Western blotting. Adipose tissues were lysed using RIPA buffer (Life technologies,
Grand Island, NY) with protease and phosphatase inhibitor cocktail (Life technologies,
Grand Island, NY) for 30 min in ice, and then centrifuged at 12,000 x g for 20 min at
4 °C. The supernatants were taken into new tubes for protein quantitation assay using
DCTM protein assay kit II (Bio-Rad, Hercules, CA). 50 µg of each lysates were
separated on 10 % SDS-polyacrylamide gel and transferred to PVDF membranes. The
membranes were blocked for 1 h at room temperature, washed 4 times with TBS-T
for 5 min and incubated overnight with a primary antibody at 4 °C. The membranes
were then washed 3 times with TBS-T and incubated with a secondary antibody at RT.
To detect the target proteins, the membranes were incubated with ClarityTM Western
ECL Blotting substrate (Bio-Rad, Hercules, CA) for 5 min using an Image Station
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4000MM instrument (Carestream Health, New Heaven, CT). The band intensity was
determined by ImageJ software (U.S. National Institutes of Health).

4.4. Statistical analysis
All statistical analyses were performed in Excel and statistical significances
were evaluated with independent t-test.

4.5. Results
4.5.1. High-fat diet (HFD) for 16 weeks induced obesity but decreased adipose
tissue functions via TNFα.
In order to examine if HFD administration for 16 weeks, which is relatively
prolonged and chronic over-nutrition period, induces adipocyte dysfunction through
TNFα production, adipogenic function-related genes such as PPARγ, perilipin and
FAS and FABP4 were analyzed in adipose tissue. As shown in Fig. 18, HFD for 16
weeks significantly inhibited the protein expression levels of PPARγ, perilipin, FAS
and FABP4 (p<0.001), suggesting obesity-induced adipose tissue dysfunction.
However, HFD-induced suppression of perilipin and FABP4, were in part restored
and PPARγ was completely recovered in the absence of TNFα, suggesting HFD or
TNFα itself is able to induce adipose tissue dysfunction but the inhibitory effects of
TNFα is a PPARγ-dependent.
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Figure 18. Changes in adipogenic protein expression in adipose tissue from LFDTNFα+/+ (WT-LF), HFD-fed TNFα+/+ (WT-HF) and HFD-fed TNFα-/(TNFα KO-HF). A representative immunoblot showing PPARγ, perilipin, FAS
and FABP4 protein levels in adipose tissues. The western blots are quantified by
Image J software and presented as relative expression of control. Six mice were
used in each analysis. Significant difference was determined by independent ttest (*p<0.05 vs. WT-LF, **p<0.01vs. WT-LF, ***p<0.001 vs. WT-LF,
#p<0.05 vs. WT-HF, ##p<0.01 vs. WT-HF, ###p<0.001 vs. WT-HF)

4.5.2. TNFα inhibited adipose tissue PPARγ gene expression.
To confirm TNFα-induced changes in the gene expression, the adipogenic
genes were analyzed by RT-PCR. Consistent with the protein data, mRNA expression
levels of PPARγ and perilipin were significantly upregulated in the absence of TNFα,
whereas the mRNA expression of FAS was not significant at p<0.05 despite an
upward tendency. Also, these data are consistent with TNFα-treated mature adipocyte
which represented a significant decrease in the mRNA expression of perilipin and
PPARγ but not in FAS mRNA expression.
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Figure 19. The mRNA expression of adipogenic genes such as PPARγ, perilipin,
FAS in TNFα+/+ (WT-HF) and TNFα-/-(TNFα KO-HF). The data presented
are relative values expressed in relation to endogenous β-actin (mean±S.E.). Six
mice were used in each analysis. Significant difference was determined by
independent t-test (*p<0.05 vs. WT-HF, **p<0.01vs. WT-HF, ***p<0.001 vs.
WT-HF)

4.5.3. Obesity-induced TNFα inhibited adipose tissue functions.
To ascertain the role of TNFα in adipose tissue function, glucose metabolism
and triglyceride (TG) dynamics-related genes were analyzed. As shown in Fig. 20,
glucose metabolism-related genes, TNFα deficiency significantly upregulated the
mRNA expression adiponectin and GLUT4 at least 20-fold (p<0.05). In addition, the
marker genes for TG synthesis (DGAT1) and TG breakdown (ATGL) were
significantly increased in the absence of TNFα (p<0.001), suggesting that TNFα plays
an important role in adipose tissue dysfunction in obesity.
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Figure 20. The mRNA expression of GLUT4, adiponectin, DGAT1 and ATGL in
TNFα+/+ (WT-HF) and TNFα-/-(TNFα KO-HF). The data presented are
relative values expressed in relation to endogenous β-actin (mean±S.E.). Six
mice were used in each analysis. Significant difference was determined by
independent t-test (*p<0.05 vs. WT-HF, **p<0.01vs. WT-HF, ***p<0.001 vs.
WT-HF)

4.5.4. Obesity-induced TNFα induced hepatic TG accumulation.
Since a loss of TNFα in HFD-induced obese mice decreased circulating FFAs
and hepatic TG contents (Salles et al., 2012), we next investigated if TNFα-induced
adipose tissue dysfunction increases hepatic accumulation. To this end, hepatic TG
contents among the groups were first analyzed. As shown in Fig. 21, HFD
significantly increased hepatic TG contents (p<0.05), whereas the TG contents in
HFD-fed TNFα-/- mice were significantly lowered as statistically similar as to LFDfed TNFα+/+, suggesting that TNFα is the causative factor that increases hepatic lipid
deposition in obesity.
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Figure 21. Hepatic TG contents from LFD-TNFα+/+ (WT-LF), HFD-fed
TNFα+/+ (WT-HF) and HFD-fed TNFα-/- (TNFα KO-HF). Hepatic TG was
extracted and analyzed using TG content measurement kit. Data are expressed as
µg/mg of liver tissue and represent the means±S.E. Six mice were used in each
analysis. Significant difference was determined by independent t-test (*p<0.05
vs. WT-LF, **p<0.01vs. WT-LF, ***p<0.001 vs. WT-LF, #p<0.05 vs. WT-HF,
##p<0.01 vs. WT-HF, ###p<0.001 vs. WT-HF)

4.5.5. Obesity-induced TNFα increased hepatic TG content.
To investigate if TNFα-induced hepatic lipid engorgement is associated with
adipose tissue dysfunction, lipogenic genes such as FAS and SCD1 were analyzed
from the liver. First, TNFα mRNA expression was analyzed and decreased in TNFαdeficient mice as expected. As shown in Fig. 22, the mRNA expression levels of FAS
and SCD1 were significantly decreased in the liver from HFD-fed TNFα+/+ mice
(p<0.01), suggesting that HFD itself decreases de novo lipogenesis genes, FAS and
SCD1 due perhaps to abundant dietary free fatty acids in HFD but increases TG
synthesis through the utilization of circulatory free fatty acids (Duarte et al., 2014).
However, the reduction of de novo lipogenesis-related genes was further decreased in
the absence of TNFα, suggesting obesity-induced TNF production causes adipose
tissue dysfunction that imposes the metabolic burden to the liver.
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Figure 22. The mRNA expression of TNFα, FAS and SCD1 in liver tissues from
LFD-TNFα+/+ (WT-LF), HFD-fed TNFα+/+ (WT-HF) and HFD-fed TNFα/- (TNFα KO-HF). The data presented are relative values expressed in relation
to endogenous β-actin (mean±S.E.). Six mice were used in each analysis.
Significant difference was determined by independent t-test (*p<0.05 vs. WTLF, **p<0.01vs. WT-LF, ***p<0.001 vs. WT-LF, #p<0.05 vs. WT-HF,
##p<0.01 vs. WT-HF, ###p<0.001 vs. WT-HF)
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5. SUMMARY
5.1. In vitro study: The effects of TNFα in adipocyte functions
In summary, we examined the role of TNFα in adipocyte functions. The
results demonstrate that TNFα treatment induces dysfunctional adipocytes through the
inhibition of adipocyte PPARγ and preadipocyte differentiation. In addition, our data
indicate that PA-induced in vitro hypertrophic adipocytes are dysfunctional, due
perhaps to overexpression of TNFα. This conclusion is supported by the data from
TNFα-treated adipocytes that showed a consistent data with hypertrophic adipocytes.
Therefore, TNFα-induced changes in gene expression during preadipocyte
differentiation and in mature adipocytes provide a molecular understanding for the
development of adipocyte dysfunction..

Figure 23. The schematic diagram depicting the possible mode of action of TNFα
in adipocytes.
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5.2. In vivo study: The role of TNFα in high-fat diet (HFD)-induced obesity
In summary, we examined the potential role that TNFα plays in adipocyte
metabolism and function in vivo. The results indicate the significant contribution of
obesity-induced TNFα production to adipocyte dysfunction, hepatic lipid deposition
and insulin resistance. Also, this study clearly indicates that diet itself is a negative
mediator that suppresses de novo lipogenesis in the liver and adipose tissue.

Figure 24. The schematic diagram depicting the underlying mechanisms by
which TNFα induces insulin resistance in obesity.
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6. DISCUSSION
In obesity, chronic low-grade inflammation has been implicated to induce
insulin resistance (IR) that links obesity to type 2 diabetes (T2DM) (Samad & Ruf,
2013). Recent research studies indicate that tumor necrosis factor α (TNFα) is a
causative factor of acquired IR and with it come many risk factors of T2DM, such as
elevated free fatty acids (FFAs) and hepatic deposition (Bouter, Geary, Langhans, &
Asarian, 2010; Salles et al., 2012). However, the molecular mechanisms that underlie
the deleterious action of TNFα in obesity have been unclear.
A direct interaction between TNFα and insulin resistance has been implicated,
as studies in obese and diabetic rodents indicate that the absence of TNFα improves
the resistance to the action of insulin to stimulate peripheral glucose uptake
(Hotamisligil et al., 1993; Uysal et al., 1997). This is further supported by the
demonstration that TNFα impairs the signaling capacity of the insulin receptor in
adipose tissue in vivo and adipocytes in vitro through the blockage of tyrosine
phosphorylation of the insulin receptors (Hotamisligil et al., 1996; Hotamisligil et al.,
1993; Stephens et al., 1997). In addition, TNFα increases the mobilization of FFAs
into the circulation, hepatic lipid deposition and elevated concentrations of
inflammatory cytokines such as MCP1 and IL-6 in HFD-induced obese mice (Salles
et al., 2012), suggesting that the association between TNFα and T2DM is a causal
relationship. However, how TNFα is interrelated with the risk factors for T2DM
should be determined.
The importance of adipose tissue function in the body has been brought up by
the observation that dysfunctional adipose tissue elevates circulating concentration of
FFAs and causes dramatic lipid engorgement in the liver and insulin resistance
(Moitra et al., 1998; Sovik et al., 1996). Adipose tissue function is maintained by
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adipocytes which constitutes almost adipose tissue. Also, preadipocyte differentiation
is required to maintain functional adipocytes. In this context, TNFα has been
implicated to compromise adipose tissue function through the downregulation of
PPARγ expression which is an essential transcriptional factor for preadipocyte
differentiation and mature adipocyte functions such as lipid and glucose metabolism.
Indeed, our data indicate that TNFα inhibited preadipocyte differentiation and mature
adipocyte functions through PPARγ in vitro, consistent with previous studies (Chae &
Kwak, 2003; Ruan et al., 2002). In addition, in vitro hypertrophic adipocytes had a
significant decrease in PPARγ but overexpressed TNFα and IL-6 mRNAs. Consistent
with in vitro data, TNFα-/- fed HFD had a significant increase in the genes such as
PPARγ, perilipin, DGAT1 and ATGL, suggesting that the development of the
inflammatory state in obesity is associated with adipocyte dysfunction. However,
HFD per se is a negative mediator of adipose tissue function as TNFα deficiency in
part restored lipogenic genes such as perilipin, FAS and FABP4.
In addition, the normal secretion of adipokines such as adiponectin is the role
of adipose tissue as endocrinal organ. Adiponectin is the important cytokine to
enhance the whole body insulin sensitivity, but especially hepatic insulin sensitivity
(Kawano & Arora, 2009; Pagano et al., 2005). Indeed, the circulating concentration of
adiponectin is decreased but hepatic insulin resistance and lipid deposition are
increased in obesity and T2DM (Kadowaki et al., 2006). To our knowledge, however,
it has not been previously reported which factor or factors alter plasma adiponectin
levels in obesity and T2DM. Our in vitro data indicate that TNFα treatment
significantly inhibited the mRNA expression of adiponectin during preadipocyte
differentiation and in mature adipocytes and that hypertrophic adipocytes had a
decrease in adiponectin mRNA expression. In addition, adiponectin mRNA
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expression significantly increased but hepatic deposition decreased in HFD-fed
TNFα-/-, suggesting that TNFα-induced adipocyte dysfunction is associated with a
decrease in adiponectin expression. However, it has been reported that circulating
adiponectin concentration is not increased in TNFα-deficient mice fed HFD for 4
weeks (Bouter et al., 2010). This could be the difference in HFD feeding period that
can also differentiate the profound effects of TNFα on adipocyte because the
circulating levels of TNFα is increased in proportion to the severity of insulin
resistance.
In conclusion, the present study provides the new insight into the casual
relationship between inflammation and insulin resistance in obesity. Our data indicate
the contribution of obesity-induced TNFα to adipocyte dysfunction that can increase
the risk factors such as the elevated circulating FFAs levels, hepatic deposition,
insulin resistance and decreased circulating concentration of adiponectin, for T2DM.
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